SCHEMBL6071309

SCHEMBL6071309

CCOC(=O)c1ccc2[nH]c3c(c2c1)CCc1cn[nH]c1-3

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 10/20 0.65
RIPK1 Q13546 8/20 0.65
KDM4E B2RXH2 7/20 0.63
MAPT P10636 6/20 0.63
HSD17B10 Q99714 6/20 0.63
ALDH1A1 P00352 6/20 0.63
MEN1 O00255 5/20 0.63
KMT2A Q03164 5/20 0.63
MAPK1 P28482 5/20 0.63
RAB9A P51151 4/20 0.63
LMNA P02545 3/20 0.63
NPC1 O15118 2/20 0.63
TSHR P16473 2/20 0.63
MPI P34949 1/20 0.63
ALOX15 P16050 3/20 0.62
SMN1; SMN2 Q16637 2/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
PLK4 O00444 1/20 0.61
DAPK3 O43293 1/20 0.61
DYRK3 O43781 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5583276 0.94 MAPT (0.66) MAPK10RIPK1KDM4EMAPTHSD17B10
SCHEMBL5583247 0.94 MAPT (0.69) MAPK10RIPK1KDM4EMAPTHSD17B10
SCHEMBL6071229 0.83 MAPK10 (0.65) MAPK10RIPK1KDM4EMAPTHSD17B10
SCHEMBL6070937 0.83 MAPK10 (0.62) MAPK10RIPK1KDM4EMAPTHSD17B10
SCHEMBL6071613 0.82 MAPK10 (0.64) MAPK10RIPK1KDM4EMAPTHSD17B10
SCHEMBL6071308 0.81 MAPK10 (0.63) MAPK10RIPK1KDM4EMAPTHSD17B10
SCHEMBL6071369 0.81 MAPK10 (0.60) MAPK10RIPK1KDM4EMAPTHSD17B10
SCHEMBL6071266 0.81 KDM4E (0.62) MAPK10RIPK1KDM4EMAPTHSD17B10
SCHEMBL6071331 0.81 MAPK10 (0.60) MAPK10RIPK1KDM4EMAPTHSD17B10
SCHEMBL6071388 0.80 MAPK10 (0.58) MAPK10RIPK1KDM4EMAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060264493-A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2006-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264493-A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K1, MAP3K19, MAP3K20 MAPK10 387/4885RIPK1 131/4885KDM4E 1799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.